<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04521465</url>
  </required_header>
  <id_info>
    <org_study_id>NTO-001</org_study_id>
    <nct_id>NCT04521465</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of NovaTears® + Omega-3 (0.2%) Eye Drops on Signs and Symptoms of Dry Eye</brief_title>
  <official_title>A Multi-Center, Single Arm, Post-Market Clinical Follow-up Study to Evaluate the Safety and Efficacy of NovaTears® + Omega-3 (0.2%) Eye Drops on Signs and Symptoms of Dry Eye</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novaliq GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novaliq GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This PMCF study is carried out following successful CE marking of NovaTears® + Omega-3 and is&#xD;
      intended to generate systematic clinical data on the safety and performance of the device&#xD;
      when used in accordance with the intended purpose.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 9, 2020</start_date>
  <completion_date type="Actual">February 17, 2021</completion_date>
  <primary_completion_date type="Actual">February 17, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective of this study is to confirm the performance, relieving symptoms and improving signs of DED, and to evaluate safety and tolerability of topical NovaTears® + Omega-3 (0.2%) eye drops, when used in accordance with its approved labeling</measure>
    <time_frame>2 months</time_frame>
    <description>This PMCF study is intended to provide systematic clinical data supporting the safety and performance of the medical device NovaTears® + Omega-3 (0.2%).</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">36</enrollment>
  <condition>Evaporative Dry Eye Disease</condition>
  <arm_group>
    <arm_group_label>NovaTears® + Omega-3</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NovaTears® + Omega-3 (Perfluorohexyloctane with 0.2% w/w Omega-3 fatty acid ethyl esters)</intervention_name>
    <description>Eye drops</description>
    <arm_group_label>NovaTears® + Omega-3</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with evaporative Dry Eye Disease&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed ICF (Informed Consent Form) and data protection form&#xD;
&#xD;
          -  Patient-reported history of DED in both eyes&#xD;
&#xD;
          -  Have an Ocular Surface Disease Index (OSD) score ≥ 25 at Visit 1&#xD;
&#xD;
          -  Have Meibomian Gland Dysfunction (MGD) at Visit 1.&#xD;
&#xD;
          -  Ability and willingness to follow instructions, including participation in all study&#xD;
             assessments and visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are pregnant, nursing or planning a pregnancy&#xD;
&#xD;
          -  Ocular surface pathology, clinically significant slit-lamp findings, abnormal lid&#xD;
             anatomy, active ocular allergies&#xD;
&#xD;
          -  Wear of contact lenses&#xD;
&#xD;
          -  Known allergy or sensitivity to the medical device or its components&#xD;
&#xD;
          -  Currently enrolled in an investigational drug or device study or have used an&#xD;
             investigational drug or device within 60 days before Visit 1.&#xD;
&#xD;
          -  Clinical site employees or immediate family members of the same&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sonja Kroesser, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Novaliq GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NTO-001 Investigational Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69121</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NTO-001 Investigational Site</name>
      <address>
        <city>Nürnberg</city>
        <zip>90403</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>August 19, 2020</study_first_submitted>
  <study_first_submitted_qc>August 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2020</study_first_posted>
  <last_update_submitted>April 14, 2021</last_update_submitted>
  <last_update_submitted_qc>April 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

